A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Alignment Healthcare, Inc. ALHC
Weak (graded 2026-07-18, not re-checked) broader-coverage candidate · Alignment Healthcare, Inc.
On FrontierLab's discovery record since 2026-07-17 (5 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-18), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 41.8% |
|---|---|
| Gross margin | 12.4% |
| Gross profits / assets | 0.42 |
| Rule of 40 | 42.6 |
| Net margin | 0.8% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 1 |
Quality checklist
- ✓ Revenue growth — 41.8% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.42 (pass ≥ 0.33)
- ✗ Gross margin — 12.4% (pass ≥ 60%)
- ✓ Cash generation
- ✗ Share dilution — 10.1%
Fundamentals — snapshot as of 2026-07-18
| Stage | Established |
|---|---|
| Share issuance (YoY) | 10.1% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | 225.4 |
| EPS (trailing) | $0.09 |
| Burn multiple | — |
| Gross-margin trend (pts) | 0.8 |
| Cash / assets | 1.12 |
| Net debt / EBITDA | -16.3 |
| Statements as of | Q1 FY2026 · filed 2026-04-30 |
Momentum context — a snapshot from 2026-07-18, not current
| Price at surface | $20.60 (as of 2026-07-18) |
|---|---|
| 52-week range | $11.625 – $25.12 |
| % off 52-wk high | -18% |
| RSI (14) | 49 |
| Relative volume | 0.5× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-07-18 (end-of-day). How grades are computed →